Abstracts tagged "functional status"

Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Lesley Ann Saketkoo¹, Reuben Escorpizo², Kevin J. Keen³, Kim Fligelstone⁴ and Oliver Distler⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, ³Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…
Abstract Number: 2444 • 2012 ACR/ARHP Annual Meeting
Restricting Back Pain Is Associated with Disability in Community-Living Older Persons
Una E. Makris¹, Liana Fraenkel², Ling Han³, Linda Leo-Summers³ and Thomas M. Gill⁴, ¹Rheumatology, UT Southwestern Medical Center, VA Medical Center, Dallas, TX, ²Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, ³Internal Medicine, Department of Medicine, New Haven, CT, ⁴Internal Medicine, Section of Geriatrics, Yale University, New Haven, CT
Background/Purpose: Although back pain is common and costly, few longitudinal studies have evaluated the association between back pain, severe enough to restrict activity (hereafter referred…
Abstract Number: 403 • 2012 ACR/ARHP Annual Meeting
The Impact of Reaching Low Disease Activity in the First Year On Future Disability and Damage in Patients with Early Rheumatoid Arthritis
Pooneh Akhavan¹, George A. Tomlinson², Paul R. Fortin³ and Claire Bombardier¹, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ³Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada
Background/Purpose: Remission has been proposed as the goal of treatment in patients with early rheumatoid arthritis (RA) by current clinical practice guidelines. Remission is ideal…
Abstract Number: 2445 • 2012 ACR/ARHP Annual Meeting
Ipsilateral Lower Extremity Joint Involvement Increases the Risk of Poor Pain and Function Outcomes After Hip or Knee Arthroplasty
Jasvinder A. Singh¹ and David Lewallen², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Orthopedics, Mayo Clinic college of medicine, Rochester
Background/Purpose: Persistent pain and functional limitation are unfavorable outcomes after knee and hip replacement, which are getting increasing attention due to a dramatic increase in…
Abstract Number: 360 • 2012 ACR/ARHP Annual Meeting
Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study
Yukitomo Urata¹, Yoshihide Nakamura² and Ken-ichi Furukawa³, ¹Rheumatology, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ³Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid…
Abstract Number: 2139 • 2012 ACR/ARHP Annual Meeting
Smoking Is Associated with Worsening Functional Status Over Time in a Diverse Cohort of Patients with Rheumatoid Arthritis
Matthew Reimert¹, Laura Trupin², Patricia P. Katz³, Edward H. Yelin⁴, Jennifer Barton² and John B. Imboden⁵, ¹Rheumatology, University of CA San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California San Francisco, San Francisco, CA, ⁴Medicine, UC San Francisco, San Francisco, CA, ⁵Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA
Background/Purpose: Although the effects of tobacco use on disease onset, severity, and response to therapy have been well studied in rheumatoid arthritis (RA), there is…
Abstract Number: 219 • 2012 ACR/ARHP Annual Meeting
Significant Functional Improvement Using Aggressive Immunomodulatory Therapy in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Ramona Mihu¹, Roger D. Rossen², Jovan Popovich³ and Sandra L. Sessoms¹, ¹Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, ³Medicine/Rheumatology, The Methodist Hospital, Houston, TX
Background/Purpose: Pulmonary disease in patients with idiopathic inflammatory myopathies, polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM) is a major cause of morbidity. Approximately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].